Clinical Trial Update: Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis [Phase 4]

View source ↗

Summary

The Phase 4 trial evaluating Rituximab for otolaryngologic manifestations of granulomatosis with polyangiitis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Granulomatosis with Polyangiitis

Drugs mentioned

• Rituximab (Rituxan) (rituximab)

Snippet

Sponsor: Hospital for Special Surgery, New York | Conditions: Granulomatosis With Polyangiitis (Wegener's Granulomatosis) | Phase 4 | Status: TERMINATED